BioHarvest Sciences: Q2 revenue up 3.8% to $8.8M; first CDMO deal signed; full-year guidance revised downward
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue rose 3.8% year-over-year to $8.8 million, with gross margin at 58% and net loss improving to $3.7 million. The company secured its first CDMO manufacturing agreement and redirected capital to manufacturing capacity, while revising full-year guidance downward for both CDMO and D2C segments.Original document: BioHarvest Sciences, Inc. [8MV0] SEC 6-K Current Report — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue rose 3.8% year-over-year to $8.8 million, with gross margin at 58% and net loss improving to $3.7 million. The company secured its first CDMO manufacturing agreement and redirected capital to manufacturing capacity, while revising full-year guidance downward for both CDMO and D2C segments.
Original document: BioHarvest Sciences, Inc. [8MV0] SEC 6-K Current Report — Aug. 11 2026